Marriott International Inc vs TransMedics Group Inc — how do they compare? Marriott International Inc trades at $349.51 (market cap $91.14B), while TransMedics Group Inc trades at $87.58 (market cap $3.10B). The key difference: Marriott International Inc is far larger — about 29.4× TransMedics Group Inc's market cap, and Marriott International Inc pays a 0.84% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| MAR | TMDX | |
|---|---|---|
Market Cap | $91.14B | $3.10B |
Sector | Consumer Cyclical | Technology |
52-Week High | $402.54 | $150.42 |
52-Week Low | $259.04 | $61.99 |
Enterprise Value | $108.45B | $3.49B |
Dividend Yield | 0.84% | — |
Signals from Pluang's Aura AI — not financial advice
Marriott International (MAR) trades at $355.34, up 1.98% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 9.62% net income margin and robust cash flow from operations of $3.21B in 2025, though its valuation remains elevated with a P/E of 36.18. Recent news highlights dividend declarations and AI-driven booking tools, while rising debt levels and Middle East weakness present challenges.
The outlook is mixed; analyst consensus leans bullish with a $387.31 price target, but high valuation and increasing debt-to-asset ratio (58.83% in 2025) cap upside potential. Key risks include regional volatility and competitive pressures, while fee revenue growth and a record pipeline offer opportunities for long-term investors.
TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.
The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.
Trailing returns across standard periods
Latest headlines on both assets
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →